2025年11月6日，美國總統唐納德·川普在白宮召開新聞發布會，正式宣布與兩家全球製藥巨頭——美國的禮來公司（Eli Lilly）及丹麥的諾和諾德公司（Novo Nordisk）達成藥品價格控制協議。這項協議被外界視為川普政府醫療政策的重要突破，旨在降低美國民眾使用降糖藥及減肥藥（特別是熱門藥物如Ozempic、Mounjaro等GLP-1類藥品）的高昂成本。

根據協議內容，這兩家公司將透過新設立的“TrumpRx”直銷平台，以大幅折扣的價格直接向美國消費者供應藥品，減少中間分銷成本及保險環節。特朗普在記者會上形容這是「美國藥品市場的一場革命」，並強調自己「打破了藥企壟斷的金錢遊戲」，要讓人民「用最便宜的價格獲得最好的藥」。

然而，就在他宣布這項重大消息的同時，現場卻發生戲劇性一幕——據報導，諾和諾德公司的一名高層主管戈登·芬德利（Gordon Findley）突然在會場內疑似身體不適，當場暈倒，導致直播一度中斷。白宮醫療人員立即趕到現場進行急救，隨後芬德利被送往醫院治療，目前情況尚穩定。雖然官方尚未對暈倒原因做出具體說明，但現場目擊者表示，他可能因壓力過大或突發心血管問題而昏厥。

這一事件迅速在全球媒體與社交網絡上引發熱議。許多網友戲稱這是「藥企高管聽到降價消息後被嚇暈」，象徵特朗普對大型製藥公司的直接挑戰。部分評論指出，這場突發事件凸顯了特朗普與醫藥產業之間長期存在的緊張關係——自他重新執政以來，便不斷批評藥企「貪婪無度」、「剝削病人」。

另一方面，金融市場對此消息反應劇烈。美股當日收盤時，禮來與諾和諾德的股價雙雙大跌約7%至10%，市值蒸發數百億美元。分析人士認為，這代表藥品行業正面臨新的價格監管時代，特別是在特朗普推動「藥品國產化」與「直銷化」政策的背景下，全球製藥巨頭可能必須重新評估其在美國市場的策略。

事件發生後，白宮發言人表示，總統對芬德利先生的健康狀況表達關切，並強調政府將繼續推進藥品價格改革，不會因個別事件而改變方向。這場新聞發布會從原本的政策發布會，瞬間成為政治與醫療界共同關注的焦點。對特朗普而言，這次事件既是一場象徵性的「人民勝利」，也是一場對製藥業既得利益的正面衝撞。而對藥企而言，這可能是美國藥品市場遊戲規則徹底改寫的開端。

On November 6, 2025, U.S. President Donald Trump held a press conference at the White House to announce a landmark drug price control agreement with two global pharmaceutical giants — Eli Lilly (USA) and Novo Nordisk (Denmark). The deal aims to drastically lower the cost of popular diabetes and weight-loss medications, particularly GLP-1 drugs such as Ozempic and Mounjaro, which have surged in demand across the United States.

Under the new agreement, both companies will sell their drugs at discounted prices through the newly launched “TrumpRx” direct-to-consumer platform, a government-endorsed distribution channel designed to bypass traditional middlemen and insurance markups. Trump hailed the initiative as “a revolution in the American pharmaceutical market,” claiming he had “broken Big Pharma’s monopoly” and would ensure Americans get “the best medicine at the lowest price.”

However, the highly publicized announcement took an unexpected turn. During the live event, Gordon Findley, a senior executive from Novo Nordisk, suddenly collapsed on stage, apparently suffering from a medical emergency. The broadcast was immediately cut off as White House medical staff rushed to provide first aid. Findley was later taken to a nearby hospital and is reportedly in stable condition. While no official cause has been disclosed, witnesses said he appeared to faint suddenly, possibly due to stress or a cardiovascular issue.

The incident quickly went viral online, with social media users joking that the executive “fainted upon hearing about the price cuts,” symbolizing the shockwaves Trump’s policy sent through the pharmaceutical industry. Analysts and commentators were quick to point out the broader significance — that this episode underscored the longstanding tension between Trump and Big Pharma. Since returning to office, Trump has repeatedly accused drug companies of “greed” and “profiting from people’s suffering.”

Wall Street reacted sharply to the news. By the end of the trading day, both Eli Lilly and Novo Nordisk saw their stock prices tumble between 7% and 10%, wiping out tens of billions in market value. Analysts said the selloff reflected growing concerns that Trump’s “direct pricing and localization” policies could usher in a new era of drug price regulation, forcing global pharmaceutical firms to overhaul their U.S. market strategies.

A White House spokesperson later confirmed that President Trump had expressed concern for Findley’s health but emphasized that the administration’s commitment to lowering drug prices remains unchanged.

What began as a policy announcement quickly turned into a moment of high drama — blending politics, health reform, and corporate shock. For Trump, the event symbolized a populist victory over powerful pharmaceutical interests. For the industry, it was a stark warning: the age of unchecked pricing power in America may be coming to an end.